期刊
BLOOD
卷 123, 期 9, 页码 1327-1335出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2013-09-528851
关键词
-
类别
资金
- Leukaemia and Lymphoma Research UK
- BBSRC [BB/I013407/1, BB/I013407/2] Funding Source: UKRI
- MRC [G0500563, G1001044] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/I013407/2, BB/I013407/1] Funding Source: researchfish
- Medical Research Council [G1001044, G0500563] Funding Source: researchfish
Clinical trials of oncolytic attenuated measles virus (MV) are ongoing, but successful systemic delivery in immune individuals remains a major challenge. We demonstrated high-titer anti-MV antibody in 16 adults with acute lymphoblastic leukemia (ALL) following treatments including numerous immunosuppressive drugs. To resolve this challenge, human bone marrow-derived mesenchymal stromal cells (BM-MSCs) were used to efficiently deliver MV in a systemic xenograft model of precursor B-lineage-ALL. BM-MSCs were successfully loaded with MV ex vivo, and MV was amplified intracellularly, without toxicity. Live cell confocal imaging demonstrated a viral hand-off between BM-MSCs and ALL targets in the presence of antibody. In a murine model of disseminated ALL, successful MV treatment (judged by bioluminescence quantification and survival) was completely abrogated by passive immunization with high-titer human anti-MV antibody. Importantly, no such abrogation was seen in immunized mice receiving MV delivered by BM-MSCs. These data support the use of BM-MSCs as cellular carriers for MV in patients with ALL.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据